BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38244135)

  • 1. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma.
    Zalay O; Mehra P; Pereira I; Malone J; Malone S
    World J Urol; 2024 Jan; 42(1):52. PubMed ID: 38244135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
    Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
    Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
    Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
    Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
    Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
    Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
    Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
    BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
    Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
    BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
    Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
    Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK).
    Siva S; Correa RJM; Warner A; Staehler M; Ellis RJ; Ponsky L; Kaplan ID; Mahadevan A; Chu W; Gandhidasan S; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Louie AV
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):941-949. PubMed ID: 32562838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
    Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
    Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
    Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
    Ali M; Koo K; Chang D; Chan P; Oon SF; Moon D; Murphy DG; Eapen R; Goad J; Lawrentschuk N; Azad AA; Chander S; Shaw M; Hardcastle N; Siva S
    Radiat Oncol; 2024 Feb; 19(1):23. PubMed ID: 38355495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.
    Siva S; Kothari G; Muacevic A; Louie AV; Slotman BJ; Teh BS; Lo SS
    Nat Rev Urol; 2017 Sep; 14(9):549-563. PubMed ID: 28631740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
    Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
    Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.
    Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV
    Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time?
    Carrasco-Esteban E; Barrionuevo-Castillo P; Domínguez-Rullán J; Gómez-Aparicio MA; Ferri-Molina M; Sáez-Bueno P; Zalabarría-Zarrabeitia Z; Scorsetti M; Arcangeli S; López-Campos F; Couñago F
    Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):163-176. PubMed ID: 36443137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
    Correa RJM; Louie AV; Staehler M; Warner A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Siva S
    J Urol; 2019 Jun; 201(6):1097-1104. PubMed ID: 30741849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus.
    Hannan R; Margulis V; Chun SG; Cannon N; Kim DW; Abdulrahman RE; Sagalowsky A; Pedrosa I; Choy H; Brugarolas J; Timmerman RD
    Cancer Biol Ther; 2015; 16(5):657-61. PubMed ID: 25800036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
    Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.